Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02406261 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT02406261 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 82 participants.
The verdict
NCT02406261, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
The purpose of this study is to study the effect of lanabecestat on how the body absorbs and processes 3 other medications, midazolam, simvastatin and donepezil and how these 3 medications affect lanabecestat when they are taken together. This study is in 2 cohorts, Cohort A is approximately 44 days long and Cohort B about 70 days only. The screening visit is required within 30 days prior to the start on the study
Interventions
- DRUG Midazolam
- DRUG Simvastatin
- DRUG Donepezil
- DRUG Lanabecestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2015-04-30 |
| Est. Completion | 2015-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02406261
The ClinicalTrials.gov registry entry for NCT02406261 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Midazolam is the first listed.
NCT02406261 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02406261 about?
NCT02406261 is a clinical study titled "A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants". The purpose of this study is to study the effect of lanabecestat on how the body absorbs and processes 3 other medications, midazolam, simvastatin and donepezil and how these 3 medications affect lanabecestat when they are taken together. This study is in 2 cohorts, Cohort A is approximately 44 days...
What is the current status of trial NCT02406261?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2015-04-30. Estimated completion is 2015-08-31.
What interventions are being tested in trial NCT02406261?
The interventions under investigation include: Midazolam (DRUG), Simvastatin (DRUG), Donepezil (DRUG), Lanabecestat (DRUG).
Who is sponsoring clinical trial NCT02406261?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.